143 related articles for article (PubMed ID: 23683749)
1. Treating basal-cell carcinoma in a real life setting.
Dummer R
Lancet Oncol; 2013 Jun; 14(7):572-3. PubMed ID: 23683749
[No Abstract] [Full Text] [Related]
2. Effect of pigmentation on photodynamic therapy.
Apalla Z; Lallas A; Sotiriou E; Ioannides D
Lancet Oncol; 2013 Aug; 14(9):e339-40. PubMed ID: 23896270
[No Abstract] [Full Text] [Related]
3. Effect of pigmentation on photodynamic therapy - Authors' reply.
Arits A; Kelleners-Smeets NW
Lancet Oncol; 2013 Aug; 14(9):e340. PubMed ID: 23896273
[No Abstract] [Full Text] [Related]
4. Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
Nijsten T
Br J Dermatol; 2015 Jan; 172(1):12. PubMed ID: 25581586
[No Abstract] [Full Text] [Related]
5. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
Arits A; Nelemans P; Kelleners-Smeets N
Br J Dermatol; 2015 Jan; 172(1):11-2. PubMed ID: 25581585
[No Abstract] [Full Text] [Related]
6. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
[No Abstract] [Full Text] [Related]
7. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Lecluse LL; Spuls PI
Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminolevulinic acid based photodynamic therapy for basal cell carcinoma: a 10-years follow-up study.
Christensen E
Stomatologija; 2013; 15(3):ii. PubMed ID: 24511763
[No Abstract] [Full Text] [Related]
10. Fractionated 5-aminolevulinic acid photodynamic therapy in the treatment of a giant recurrent superficial basal cell carcinoma.
Sotiriou E; Apalla Z; Ioannides D
Photodermatol Photoimmunol Photomed; 2009 Dec; 25(6):331-2. PubMed ID: 19906170
[No Abstract] [Full Text] [Related]
11. Noninvasive assessment for noninvasive treatments in dermato-oncology.
Segura S
Br J Dermatol; 2013 Jan; 168(1):3-4. PubMed ID: 23278556
[No Abstract] [Full Text] [Related]
12. A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes.
Sebaratnam DF; Venugopal SS; Murrell DF
J Eur Acad Dermatol Venereol; 2011 Jan; 25(1):117-8. PubMed ID: 20456551
[No Abstract] [Full Text] [Related]
13. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
14. Fibroepithelioma of Pinkus: poor response to topical photodynamic therapy.
Park MY; Kim YC
Eur J Dermatol; 2010; 20(1):133-4. PubMed ID: 19919909
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
[TBL] [Abstract][Full Text] [Related]
16. Problems associated with the use of broad-band illumination sources for photodynamic therapy.
Stringer MR
Phys Med Biol; 1995 Oct; 40(10):1733-5. PubMed ID: 8532752
[No Abstract] [Full Text] [Related]
17. Treatment of choice in superficial basal cell carcinoma.
de Haas ER
Br J Dermatol; 2015 Mar; 172(3):563. PubMed ID: 25776243
[No Abstract] [Full Text] [Related]
18. The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma.
van der Beek N; Bjerring P; Neumann HA
Br J Dermatol; 2015 Oct; 173(4):1105-6. PubMed ID: 26146762
[No Abstract] [Full Text] [Related]
19. The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma: reply from the authors.
Roozeboom MH; Arits AH; Kelleners-Smeets NW
Br J Dermatol; 2015 Oct; 173(4):1106-7. PubMed ID: 26154079
[No Abstract] [Full Text] [Related]
20. Nodular basal cell carcinoma: when in doubt, cut it out.
Brownell I
J Drugs Dermatol; 2007 Dec; 6(12):1245-6. PubMed ID: 18189068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
